News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Acetylon Pharmaceuticals to Participate on Financing Panel and Provide Corporate Update at Biotechnology Industry Organization (BIO) Investor Forum


10/9/2012 9:34:17 AM

BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals today announced that Walter Ogier, President and CEO, will participate on the panel “The New Kids on the Biotech Block: Trends in Early Stage Financing” this morning, October 9, 2012, at 9 am PT at the BIO Investor Forum in San Francisco, CA. In addition, Mr. Ogier will give a corporate presentation at 3 pm PT, including an update of its oral histone deacetylase 6 (HDAC6) inhibitor, rocilinostat (ACY-1215), which is currently in two Phase 1b combination clinical trials with Revlimid® (lenalidomide, Celgene) and Velcade® (bortezomib, Takeda Millennium) for the treatment of relapsed and relapsed/refractory multiple myeloma.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES